+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a urine test called the 3-metabolite biosensor to detect colorectal cancer CRC and precancerous polyps in adults living in Ghana, Tanzania, and South Africa. The study focuses on participants who either have symptoms of colorectal cancer, are undergoing screening colonoscopy, or have had recent colonoscopy or pathology results related to CRC or polyps. Participants will be observed using the 3-metabolite biosensor, which is designed to identify colorectal cancer and precancerous polyps from urine samples. The study includes individuals with various colonoscopy findings, including those with diagnosed CRC, adenomatous polyps, or no malignancy, and those presenting symptoms such as rectal bleeding. During the study, participants will provide urine samples for testing with the biosensor. Researchers will measure the sensitivity of the biosensor in detecting colorectal cancer and precancerous polyps over up to one year. Participants are asked to be willing to participate and meet the age criteria of 18 years or older. The study is observational and does not involve treatment interventions.

Age: 18Years +All Genders
4 locations
E

Actively Recruiting

Researchers are evaluating the use of bedaquiline compared to standard treatments to prevent tuberculosis disease in people living with HIV and close contacts of adults with drug-susceptible or rifampin-resistant tuberculosis. This Phase IIIII open-label trial aims to show that 4 weeks of bedaquiline is not less effective than current WHO-recommended regimens for preventing tuberculosis in these high-risk groups. Participants are assigned to one of three treatment groups 4 weeks of daily bedaquiline, 3 months of weekly isoniazid and rifapentine, or 6 months of daily levofloxacin. The study includes groups at high risk, such as children, adolescents, adults, pregnant people, and people living with HIV, with treatments adjusted by weight or age. Treatment durations vary by regimen, and those with rifampin-resistant tuberculosis receive levofloxacin. During the study, participants undergo safety and treatment completion assessments up to 18 or 36 weeks depending on the group. Researchers monitor for adverse events, treatment adherence, and incidence of tuberculosis disease for up to 72 weeks after treatment starts. Laboratory tests, chest x-rays, and pregnancy tests are conducted before enrollment, and safety is closely followed throughout the study period lasting over one year from treatment initiation.

All AgesAll GendersPhase 2Phase 3
8 locations
I

Actively Recruiting

This research aims to evaluate cancer treatment outcomes among children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries LMICs. It focuses on acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, conditions where treatment success varies widely between high-income and LMICs due to factors like delayed diagnosis and limited access to quality care. The study seeks to inform future efforts to improve cancer care and reduce treatment failures in these regions. The study involves a retrospective review of medical records from participating oncology centers in countries including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any type of cancer diagnosis who received substantial anti-cancer treatment such as chemotherapy, surgery, radiation, or immunotherapy. Special attention is given to patients with ALL or LBL to assess therapy-related toxicities and treatment outcomes over a three-year follow-up period. Participants medical records will be analyzed to estimate the incidence of treatment failure, including relapse or progression, and therapy-related severe toxicities. Data on event-free survival and overall survival will also be collected. No experimental treatments are administered, as this is a purely observational study. The study period covers up to three years from each patients cancer diagnosis, using existing health data to better understand treatment challenges and outcomes in LMICs.

Age: 0Years - 21YearsAll Genders
7 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the real-world effectiveness of a four-day Afrocentric sexual and reproductive health curriculum designed for health professional students in Tanzania. This study involves medical, nursing, and midwifery students from three universities who are pre-final year students. The curriculum aims to improve knowledge, attitudes, and clinical skills related to sexual and reproductive health across diverse populations and issues. Participants will receive a comprehensive four-day curriculum covering sexual health throughout life, male and female sexual dysfunctions, key populations such as LGBT persons and sex workers, sexual violence, clinical skills, ethics, policy writing, community resources, and cultural considerations. This curriculum is delivered at the State University of Zanzibar, Kilimanjaro Christian University, and the University of Dodoma. Participants will complete surveys before the training, immediately after, and again at 3 and 12 months to measure changes in their sexual health knowledge, attitudes, and counseling skills. Faculty delivering the curriculum will also be evaluated for knowledge and teaching skills. The study will assess whether the curriculum improves and maintains these outcomes in a real educational setting and evaluate the trainings implementation and faculty outcomes.

Age: 18Years +All GendersPhase Not Applicable
3 locations
E

Actively Recruiting

Researchers are evaluating the use of nanopore sequencing as a method for diagnosing breast cancer in Tanzania, aiming to determine if it is as effective as the current standard of care. This study focuses on patients with suspected breast cancer and explores whether this new sequencing technology can provide faster and more cost-efficient diagnosis, which could improve treatment planning and outcomes, especially in resource-limited settings. Patients with suspected breast cancer undergoing biopsy or surgical resection will have excess fresh tissue samples tested using nanopore sequencing alongside the standard methods, which include histopathology and biomarker analysis for estrogen receptor, progesterone receptor, and HER2 status. The study investigates low-pass whole genome sequencing and DNA methylation-based classification to identify invasive ductal breast cancer and its subtypes. The goal is to provide results within hours in a point-of-care setting without changing patient treatment based on the new sequencing results. Participants will have their excess tissue preserved for DNA extraction and analysis. Researchers will measure how well nanopore sequencing matches the current standard, its feasibility, and the time it takes to deliver results. Patient quality of life and experiences during their healthcare journey will also be assessed at various timepoints. The study is expected to last about one year from the start of enrollment, with final evaluations after completion.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Researchers are investigating new treatment options for adults with newly diagnosed, drug-sensitive pulmonary tuberculosis through a phase 2BC open-label platform study. The trial compares several experimental drug regimens with a standard control treatment to assess efficacy and safety. Participants include adults aged 18 to 65 years with confirmed pulmonary tuberculosis sensitive to rifampicin and isoniazid. The study aims to optimize doses of existing drugs and introduce new medications to improve treatment outcomes. The study is divided into three stages. In stage 1, participants are randomly assigned to the control or one of two experimental arms containing high-dose rifampicin and other drugs for 12 to 17 weeks. Stage 2 adds an experimental arm including the drug BTZ-043, with participants allocated across four arms in varying ratios. Stage 3 begins after stages 1 and 2 complete enrollment, comparing the control arm with two new experimental arms involving novel drug combinations. Treatments are given once daily, with dosages adjusted by arm and weight. Participants will undergo sputum testing, chest X-rays, and molecular tests to confirm tuberculosis and drug sensitivity before enrollment. During the study, researchers will monitor participants through regular clinical assessments, laboratory tests, and electrocardiograms to track treatment response and safety. The main outcomes measured include time to stable culture conversion and changes in mycobacterial load. Safety is evaluated by recording adverse events and laboratory abnormalities over the treatment period, with follow-up continuing up to 12 months after randomization.

Age: 18Years - 65YearsAll GendersPhase 2
10 locations
E

Actively Recruiting

Researchers are evaluating new treatment regimens for pulmonary tuberculosis TB that aim to be faster while maintaining safety and effectiveness. This trial is conducted by the UNITE4TB consortium, a collaboration of universities and pharmaceutical companies, funded by the European Union. The study focuses on adults with newly diagnosed rifampicin-susceptible pulmonary TB and includes both drug-susceptible and potentially drug-resistant cases to find improved therapies. The trial has two main parts. In Phase 2B, up to 700 participants will be randomly assigned to one of several treatment groups, including a standard 24-week regimen and up to 16-week novel regimens combining new drugs like BTZ-043 and GSK3036656 with existing TB medications. Phase 2C will involve up to 1800 participants receiving selected regimens from Phase 2B for varying durations between 8 and 16 weeks. The study drugs are given orally with specific doses, and treatment combinations may change during the trial. Participants will be followed for a total of 72 weeks to monitor treatment response and safety. Assessments include measuring the time to positivity of sputum cultures, adverse events, and treatment outcomes such as relapse or failure. Safety monitoring covers serious and special interest adverse events. The trial includes regular visits and laboratory tests to evaluate the effectiveness and tolerability of the treatments over the duration of the study.

Age: 18Years +All GendersPhase 2
11 locations
S

Actively Recruiting

Researchers are studying how individual health behaviors and broader societal factors like environment, policies, and health system quality affect health outcomes such as death and the development of chronic diseases. This study also explores genetic influences on non-communicable diseases through both a cross-sectional and a prospective cohort approach. It aims to understand these relationships across different socioeconomic and health resource settings worldwide. Participants are adults aged 35 to 70 years at enrollment. The study involves observing various health-related behaviors, societal determinants including built environment, food and nutrition policies, psychosocial and socioeconomic factors, and tobacco use. Researchers will track the incidence of chronic diseases like cardiovascular disease, cancer, respiratory conditions, diabetes, kidney disease, obesity, hypertension, and injuries over time, without administering any specific treatments. Participants will be followed for an average of 10 years, during which researchers will monitor health events such as new cases of cardiovascular disease and other illnesses, hospitalizations, and mortality. Data will be collected on genetic factors and changes in risk factors like smoking and diet. The study measures the impact of health systems and environmental influences on outcomes. Participants will be involved through regular assessments but will not receive interventions as this is an observational study.

Age: 35Years - 70YearsAll Genders
34 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two sorfequiline-based treatment regimens combined with pretomanid and linezolid for adults aged 18 to 65 with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. This phase 2, randomized, multi-center, partially blinded trial involves about 100 participants in South Africa and Tanzania and aims to assess treatment safety and bacterial culture conversion times. Participants are randomly assigned to one of two oral treatment groups one receives a loading dose regimen of sorfequiline 200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks, and the other receives sorfequiline 100 mg daily for 17 weeks. Both groups also take pretomanid 200 mg and linezolid 600 mg daily, with the treatment administered once daily with food. The trial includes a screening period up to 11 days before treatment, a 17-week treatment period, and a 52-week follow-up after treatment ends. During the study, participants will undergo safety monitoring including assessments of adverse events, ECGs, vital signs, lab tests, vision checks, and peripheral neuropathy evaluations. Researchers will also measure treatment efficacy by monitoring time to stable sputum culture conversion and treatment outcomes at 26 and 52 weeks post-treatment. Pharmacokinetics and quality of life are additionally assessed throughout the study duration.

Age: 18Years - 65YearsAll GendersPhase 2
12 locations
P

Actively Recruiting

This research aims to develop and test a locally tailored intervention called P-KIDs CARE to improve the triage process for injured children in Tanzania. The study focuses on pediatric injury patients, family members, and healthcare providers in two health facilities in the Kilimanjaro Region. Researchers want to understand the barriers to timely care and improve assessment, stabilization, and referral processes to reduce delays in receiving definitive treatment. The P-KIDs CARE intervention includes two main parts training healthcare providers with the World Health Organizations Basic Emergency Care Course, which uses presentations and hands-on practice, and an online decision support tool adapted for local needs. This tool incorporates models to assess mortality risk and assist with referral decisions. The intervention will be developed through workshops and refined with feedback from providers and community members before being piloted in the study facilities. Participants will include about 200 pediatric injury patients enrolled in a registry, 10 healthcare providers, and family members of patients. The study involves interviews, focus groups, surveys, and exit interviews to evaluate how feasible and acceptable the intervention is. Researchers will track outcomes like mortality, time to definitive care, patient disposition, and morbidity using tools such as the Glasgow Outcomes Scale-Extended Pediatrics. Data collection will occur over multiple years, including baseline and post-intervention periods separated by 1.5 years.

All AgesAll GendersPhase Not Applicable
1 location

1-10 of 13

1